MX2011011374A - Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma. - Google Patents
Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma.Info
- Publication number
- MX2011011374A MX2011011374A MX2011011374A MX2011011374A MX2011011374A MX 2011011374 A MX2011011374 A MX 2011011374A MX 2011011374 A MX2011011374 A MX 2011011374A MX 2011011374 A MX2011011374 A MX 2011011374A MX 2011011374 A MX2011011374 A MX 2011011374A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- pharmaceutical composition
- oral pharmaceutical
- hydrophilic drug
- self micro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe una composición farmacéutica oral auto-microemulsificante de un fármaco hidrofílico o su sal farmacéuticamente aceptable y su método de preparación. La composición comprende un fármaco hidrofílico tal como bendamustina o gemcitabina, solvente, tensoacitvo y un portador hirofílico, y tiene buena biodisponibilidad y estabilidad. Ese portador hidrofílico es compatible con la solución del fármaco y el tensoactivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17290109P | 2009-04-27 | 2009-04-27 | |
PCT/CN2010/000577 WO2010124525A1 (zh) | 2009-04-27 | 2010-04-27 | 亲水性药物之自微乳化医药组合物及其制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2011011374A true MX2011011374A (es) | 2012-02-08 |
MX349014B MX349014B (es) | 2017-07-06 |
Family
ID=42992661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011011374A MX349014B (es) | 2009-04-27 | 2010-04-27 | Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma. |
Country Status (21)
Country | Link |
---|---|
US (3) | US20100273730A1 (es) |
EP (2) | EP2425818A4 (es) |
JP (1) | JP5753157B2 (es) |
KR (1) | KR101759750B1 (es) |
CN (1) | CN102427803B (es) |
AU (1) | AU2010242461B2 (es) |
BR (1) | BRPI1011764A2 (es) |
CA (1) | CA2760039C (es) |
CO (1) | CO6470799A2 (es) |
ES (1) | ES2831037T3 (es) |
HK (1) | HK1165701A1 (es) |
IL (1) | IL215988A (es) |
MX (1) | MX349014B (es) |
MY (1) | MY174001A (es) |
NZ (1) | NZ596657A (es) |
RU (1) | RU2532362C2 (es) |
SG (1) | SG175808A1 (es) |
TW (1) | TWI461212B (es) |
UA (1) | UA105042C2 (es) |
WO (1) | WO2010124525A1 (es) |
ZA (1) | ZA201108686B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE031208T2 (hu) | 2010-01-28 | 2017-07-28 | Eagle Pharmaceuticals Inc | Bendamusztin kiszerelései |
JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
CN103037851A (zh) * | 2010-06-02 | 2013-04-10 | 安斯泰来德国有限公司 | 苯达莫司汀的口服剂型 |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2943668T3 (es) | 2012-03-20 | 2023-06-15 | Eagle Pharmaceuticals Inc | Composiciones líquidas de bendamustina para su uso en un método para tratar afecciones que responden a la bendamustina en pacientes que requieren volúmenes reducidos para administración |
HUE064884T2 (hu) | 2012-03-20 | 2024-04-28 | Eagle Pharmaceuticals Inc | Bendamusztin kiszerelések |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
ES2957541T3 (es) | 2013-08-27 | 2024-01-22 | Vasilios Voudouris | Composiciones farmacéuticas de bendamustina |
IN2014CH00151A (es) * | 2014-01-13 | 2015-07-17 | Hetero Research Foundation | |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP3174542A4 (en) | 2014-07-29 | 2018-01-03 | TherapeuticsMD, Inc. | Transdermal cream |
SG11201703593PA (en) * | 2014-11-04 | 2017-06-29 | Innopharmax Inc | Oral administration of unstable or poorly-absorbed drugs |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9861629B1 (en) | 2015-10-07 | 2018-01-09 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
US10335405B1 (en) * | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
EP3463298B1 (en) * | 2016-06-02 | 2021-09-01 | Innopharmax, Inc. | Metronomic oral gemcitabine for cancer therapy |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
WO2019051437A1 (en) * | 2017-09-11 | 2019-03-14 | Board Of Regents, The University Of Texas System | COMPOSITIONS FOR ENHANCED MEDICATION DELIVERY |
CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
CA3169441A1 (en) * | 2020-04-13 | 2021-10-21 | US Nano Food & Drug INC | Basic chemotherapeutic intratumour injection formulation |
CN112006986A (zh) * | 2020-08-07 | 2020-12-01 | 厦门大学 | 一种维生素e琥珀酸酯聚乙二醇纳米胶束及其制备方法和应用 |
CN114397381A (zh) * | 2021-12-17 | 2022-04-26 | 南京农业大学 | 一种沼液中阿莫西林的提取及含量检测方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
WO1995014037A1 (en) * | 1993-11-17 | 1995-05-26 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
CN1173742C (zh) * | 1997-12-26 | 2004-11-03 | 山之内制药株式会社 | 缓释药物组合物 |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US7217735B1 (en) * | 1999-04-09 | 2007-05-15 | Au Jessie L-S | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US7309696B2 (en) * | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
KR100915741B1 (ko) * | 2001-06-15 | 2009-09-04 | 코너스톤 파마슈티칼스 | 표적 조직 및 세포를 치료하기에 유용한 나노입자를함유하는 약제학적 및 진단학적 조성물 |
TNSN03139A1 (fr) * | 2001-06-21 | 2005-12-23 | Pfizer Prod Inc | Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle |
US7053076B2 (en) * | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
DE10306724A1 (de) * | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
MXPA04010778A (es) * | 2002-05-03 | 2005-03-07 | Janssen Pharmaceutica Nv | Microemulsiones polimericas. |
WO2004017944A1 (en) | 2002-08-23 | 2004-03-04 | Neopharm, Inc. | Liposomal gemcitabine compositions for better drug delivery |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
CN1593405A (zh) * | 2004-07-09 | 2005-03-16 | 沈阳药科大学 | 一种氟康唑液体型组方及其制剂 |
EP1674081A1 (de) * | 2004-12-23 | 2006-06-28 | KTB Tumorforschungsgesellschaft mbH | Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge |
CA2640598A1 (en) | 2006-02-03 | 2007-08-09 | Noboru Yamazaki | Liposome preparation |
EP2001439A2 (en) * | 2006-03-07 | 2008-12-17 | Novavax, Inc. | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same |
DK2197429T3 (en) * | 2007-09-03 | 2016-05-30 | Nanotherapeutics Inc | Particulate compositions for delivery of poorly soluble drugs |
-
2010
- 2010-04-26 US US12/767,293 patent/US20100273730A1/en not_active Abandoned
- 2010-04-27 SG SG2011078912A patent/SG175808A1/en unknown
- 2010-04-27 CA CA2760039A patent/CA2760039C/en active Active
- 2010-04-27 JP JP2012507575A patent/JP5753157B2/ja active Active
- 2010-04-27 TW TW099113339A patent/TWI461212B/zh active
- 2010-04-27 UA UAA201113932A patent/UA105042C2/uk unknown
- 2010-04-27 RU RU2011148140/15A patent/RU2532362C2/ru active
- 2010-04-27 MY MYPI2011005198A patent/MY174001A/en unknown
- 2010-04-27 AU AU2010242461A patent/AU2010242461B2/en active Active
- 2010-04-27 EP EP10769214A patent/EP2425818A4/en not_active Withdrawn
- 2010-04-27 CN CN201080018431.0A patent/CN102427803B/zh active Active
- 2010-04-27 KR KR1020117028150A patent/KR101759750B1/ko active IP Right Grant
- 2010-04-27 EP EP16159341.3A patent/EP3045165B1/en active Active
- 2010-04-27 NZ NZ596657A patent/NZ596657A/en unknown
- 2010-04-27 ES ES16159341T patent/ES2831037T3/es active Active
- 2010-04-27 BR BRPI1011764A patent/BRPI1011764A2/pt not_active Application Discontinuation
- 2010-04-27 MX MX2011011374A patent/MX349014B/es active IP Right Grant
- 2010-04-27 WO PCT/CN2010/000577 patent/WO2010124525A1/zh active Application Filing
-
2011
- 2011-10-27 IL IL215988A patent/IL215988A/en active IP Right Grant
- 2011-11-22 CO CO11159571A patent/CO6470799A2/es not_active Application Discontinuation
- 2011-11-25 ZA ZA2011/08686A patent/ZA201108686B/en unknown
-
2012
- 2012-06-25 HK HK12106178.7A patent/HK1165701A1/xx unknown
-
2015
- 2015-03-26 US US14/669,233 patent/US20150196537A1/en not_active Abandoned
-
2019
- 2019-05-23 US US16/420,581 patent/US20190275006A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX349014B (es) | Composicion farmaceutica oral auto-microemulsificante de un farmaco hidrofilico y metodo de preparacion de la misma. | |
WO2011012816A3 (fr) | Formulation pharmaceutique | |
AU2016219654A1 (en) | Crystallization method and bioavailability | |
WO2009006590A3 (en) | Docetaxel process and polymorphs | |
WO2008131114A3 (en) | Pharmaceutical formulations containing lipoic acid derivatives | |
WO2011042918A3 (en) | Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof | |
BRPI0910758A2 (pt) | composição sólida termoestável, composição farmacêutica, processos para a preparação de uma composição sólida termoestável e de uma composição farmacêutica, método para melhorar a biodisponibilidade de um ingrediente farmaceuticamente ativo, e, produto | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
WO2010117738A3 (en) | Solid state forms of sitagliptin salts | |
WO2010092090A3 (en) | Novel salts of sitagliptin | |
LT2808325T (lt) | Pakeistieji azolai, antivirusinis aktyvus ingredientas, farmacinė kompozicija, jų gavimo ir panaudojimo būdas | |
IT1404931B1 (it) | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . | |
WO2011120904A3 (en) | A fast dissolving pharmaceutical composition | |
WO2011009938A3 (en) | Stambomycin and derivatives, their production and their use as drugs | |
WO2010049449A3 (en) | Novel salts of sunitinib | |
JO3112B1 (ar) | تركيبة دوائية سريعة التحلل | |
BR112013013903A2 (pt) | preparação farmacêutica aquosa estável pronta para uso de cetrorelix para administração parenteral, processo para a fabricação de uma preparação farmacêutica aquosa estável pronta para uso de cetrorelix para uso de cetrorelix para administração parenteral | |
MX2012007393A (es) | Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam. | |
AU2013338098A8 (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof | |
WO2012108631A3 (en) | Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof | |
WO2013062332A3 (ko) | 시링가레시놀을 포함하는 혈관 노화 억제용 조성물 | |
MX2012005596A (es) | Derivados de difenil azepano como inhibidores de reabsorcion de monoaminas. | |
WO2009121946A3 (en) | Process for the preparation of optically enriched clopidogrel | |
AP2010005204A0 (en) | New addition salts of angiotensinconverting enzymeir preparation and pharmaceutical compositions coninhibitors with no donor acids, a process for the taining them | |
MX2010008778A (es) | Derivados de 3-alquil-piperazina y usos de la misma. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |